Health Catalyst, Inc. (NASDAQ:HCAT) insider Linda Llewelyn sold 3,098 shares of Health Catalyst stock in a transaction dated Thursday, April 1st. The stock was sold at an average price of $47.67, for a total transaction of $147,681.66. Following the completion of the sale, the insider now owns 42,027 shares of the company’s stock, valued at approximately $2,003,427.09. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Linda Llewelyn also recently made the following trade(s):

  • On Monday, February 1st, Linda Llewelyn sold 1,717 shares of Health Catalyst stock. The stock was sold at an average price of $49.15, for a total transaction of $84,390.55.

Shares of Health Catalyst stock opened at $47.30 on Thursday. The firm has a market capitalization of $2.08 billion, a PE ratio of -21.02 and a beta of 0.62. The company has a current ratio of 4.90, a quick ratio of 4.90 and a debt-to-equity ratio of 0.55. The firm’s 50 day moving average is $47.96 and its 200 day moving average is $42.42. Health Catalyst, Inc. has a 1 year low of $23.62 and a 1 year high of $55.07.

Health Catalyst (NASDAQ:HCAT) last posted its earnings results on Thursday, February 25th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.23. Health Catalyst had a negative net margin of 48.17% and a negative return on equity of 25.57%. The business had revenue of $53.28 million for the quarter, compared to the consensus estimate of $52.21 million. As a group, research analysts anticipate that Health Catalyst, Inc. will post -1.56 earnings per share for the current year.

Several equities analysts have commented on the stock. Piper Sandler raised their target price on shares of Health Catalyst from $50.00 to $54.00 and gave the company an “overweight” rating in a report on Friday, February 26th. SVB Leerink raised their target price on shares of Health Catalyst from $40.00 to $53.00 and gave the company an “outperform” rating in a report on Thursday, March 4th. Smith Barney Citigroup raised their target price on shares of Health Catalyst from $40.00 to $49.00 in a report on Tuesday, December 15th. Canaccord Genuity raised their target price on shares of Health Catalyst from $43.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, January 7th. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell raised their target price on shares of Health Catalyst from $40.00 to $49.00 in a report on Tuesday, December 15th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $44.53.

Large investors have recently bought and sold shares of the stock. Arizona State Retirement System acquired a new stake in Health Catalyst during the 4th quarter worth approximately $201,000. QS Investors LLC acquired a new stake in Health Catalyst during the 4th quarter worth approximately $221,000. Cornerstone Investment Partners LLC acquired a new stake in Health Catalyst during the 4th quarter worth approximately $224,000. Amalgamated Bank acquired a new position in shares of Health Catalyst in the 4th quarter worth approximately $229,000. Finally, Element Pointe Advisors LLC acquired a new position in shares of Health Catalyst in the 4th quarter worth approximately $248,000. Institutional investors and hedge funds own 94.18% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The company was formerly known as HQC Holdings, Inc and changed its name to Health Catalyst, Inc in March 2017.

Further Reading: Put Option Volume

Insider Buying and Selling by Quarter for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.